Maria L Amaya

13PUBLICATIONS
128CO-AUTHORS
Regenerative medicine (incl. stem cells)Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Gene and molecular therapyMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jul 24, 2026
A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia.

|Jul 17, 2026
Weakened macrophage antibacterial capacity in myelodysplastic syndrome.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Feb 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

Michael K Jones, Jesse Sanchez, Megan Connor

|Nov 14, 2025
Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.

Tianyi Ling, Cristiana O'Brien, Jonathan R St-Germain

Pageof 3

Frequent Collaborators

7 joint publications

Daniel A Pollyea

4 joint publications

Amanda Winters

4 joint publications

Christine McMahon

3 joint publications

Austin E Gillen